Total Payments
$1.2M
2024 Payments
$142,776
Companies
24
Transactions
1,165
Medicare Patients
3,896
Medicare Billing
$2.2M
Payment Breakdown by Category
Other$781,136 (67.8%)
Travel$202,475 (17.6%)
Consulting$130,451 (11.3%)
Food & Beverage$31,557 (2.7%)
Education$6,873 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $781,136 | 300 | 67.8% |
| Travel and Lodging | $202,475 | 356 | 17.6% |
| Consulting Fee | $130,451 | 38 | 11.3% |
| Food and Beverage | $31,557 | 458 | 2.7% |
| Education | $6,873 | 13 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $347,400 | 300 | $0 (2023) |
| ABBVIE INC. | $243,235 | 319 | $0 (2024) |
| Janssen Biotech, Inc. | $174,100 | 160 | $0 (2024) |
| PFIZER INC. | $98,030 | 95 | $0 (2024) |
| Celgene Corporation | $70,476 | 50 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $65,419 | 56 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $50,272 | 47 | $0 (2024) |
| UCB, Inc. | $38,232 | 49 | $0 (2019) |
| Lilly USA, LLC | $36,723 | 49 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $25,875 | 10 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142,776 | 140 | Janssen Biotech, Inc. ($76,870) |
| 2023 | $109,317 | 111 | Janssen Biotech, Inc. ($58,538) |
| 2022 | $131,369 | 160 | Janssen Scientific Affairs, LLC ($73,627) |
| 2021 | $85,935 | 99 | E.R. Squibb & Sons, L.L.C. ($28,167) |
| 2020 | $71,776 | 56 | Janssen Scientific Affairs, LLC ($19,816) |
| 2019 | $261,162 | 230 | Janssen Scientific Affairs, LLC ($67,118) |
| 2018 | $172,275 | 177 | Janssen Scientific Affairs, LLC ($77,156) |
| 2017 | $177,883 | 192 | Janssen Scientific Affairs, LLC ($83,098) |
All Payment Transactions
1,165 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/08/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $124.80 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $98.31 | General |
| Category: Immunology | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $1,228.92 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $636.88 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $149.93 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $98.94 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.08 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 11/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | Cash or cash equivalent | $184.92 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $1,313.70 | General |
| Category: Immunology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Immunology | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 10/28/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $6.05 | General |
| Category: Immunology | ||||||
| 10/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 10/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Travel and Lodging | In-kind items and services | $1,098.38 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $113.37 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Immunology | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA | Food and Beverage | Cash or cash equivalent | $44.00 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,055 | 25,750 | $1.2M | $576,898 |
| 2022 | 17 | 909 | 23,376 | $898,449 | $502,083 |
| 2021 | 17 | 994 | 26,145 | $1.2M | $596,651 |
| 2020 | 16 | 938 | 23,654 | $851,829 | $486,357 |
Total Patients
3,896
Total Services
98,925
Medicare Billing
$2.2M
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 19 | 20,700 | $517,500 | $358,572 | 69.3% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 11 | 3,640 | $339,750 | $95,728 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 214 | 309 | $45,732 | $27,019 | 59.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 67 | 67 | $50,250 | $13,461 | 26.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 35 | 135 | $27,000 | $12,414 | 46.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 90 | 90 | $58,175 | $10,287 | 17.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 52 | 52 | $30,128 | $9,620 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 120 | 141 | $14,100 | $8,596 | 61.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 95 | 96 | $36,250 | $7,880 | 21.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 59 | 59 | $13,452 | $6,339 | 47.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 57 | $8,208 | $5,389 | 65.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 35 | 35 | $18,720 | $4,237 | 22.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 53 | 53 | $18,450 | $4,188 | 22.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 23 | 23 | $13,163 | $4,167 | 31.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 45 | 45 | $6,705 | $3,317 | 49.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 24 | $6,720 | $3,161 | 47.0% |
| 43450 | Dilation of esophagus | Facility | 2023 | 41 | 41 | $5,843 | $1,336 | 22.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 54 | $5,400 | $1,123 | 20.8% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 27 | 129 | $785.00 | $64.93 | 8.3% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 15 | 22,201 | $518,653 | $381,780 | 73.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 128 | 215 | $31,820 | $19,005 | 59.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 202 | 249 | $24,900 | $16,270 | 65.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 26 | 148 | $29,600 | $14,978 | 50.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 67 | 67 | $50,250 | $12,708 | 25.3% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 16 | 16 | $48,000 | $9,346 | 19.5% |
About Dr. Charles Sninsky, MD
Dr. Charles Sninsky, MD is a Gastroenterology healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811912561.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Sninsky, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $142,776 received in 2024. These payments were reported across 1,165 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($781,136).
As a Medicare-enrolled provider, Sninsky has provided services to 3,896 Medicare beneficiaries, totaling 98,925 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Gainesville, FL
- Active Since 07/13/2006
- Last Updated 09/09/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1811912561
Products in Payments
- STELARA (Biological) $431,735
- XELJANZ (Drug) $94,806
- Humira (Biological) $82,675
- ZEPOSIA (Drug) $76,188
- TREMFYA (Drug) $70,890
- Ozanimod (Drug) $51,121
- RINVOQ (Biological) $50,964
- Entyvio (Biological) $38,611
- Cimzia (Drug) $38,232
- ENTYVIO (Biological) $37,677
- OMVOH (Drug) $25,341
- SKYRIZI (Biological) $24,068
- HUMIRA (Biological) $22,056
- SIMPONI (Biological) $8,219
- REMICADE (Biological) $6,540
- SIMPONI ARIA (Biological) $4,223
- VELSIPITY (Drug) $3,125
- CIMZIA (Drug) $2,092
- ZENPEP (Drug) $102.21
- INFLECTRA (Biological) $87.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Gainesville
Peter Draganov, Md, MD
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Christopher Forsmark, Md, MD
Gastroenterology — Payments: $94,323
Gastroenterology $94,323
Ahmed Ouni
Gastroenterology — Payments: $31,897
Gastroenterology $31,897
Virginia Clark, Md, MD
Gastroenterology — Payments: $23,687
Gastroenterology $23,687
Dr. Roniel Cabrera, Md, MD
Gastroenterology — Payments: $22,274
Gastroenterology $22,274
Dr. Justin Forde, M.d, M.D
Gastroenterology — Payments: $20,763
Gastroenterology $20,763